HC Surgical Specialists Ltd AI Stock Analysis
Want to see SG:1B1 full AI Analyst Report?
HC Surgical Specialists Ltd (1B1) AI Stock Analysis
HC Surgical Specialists Ltd
(SGX:1B1)
The stock's score of 73 is primarily supported by its strong financial performance, featuring a rock-solid balance sheet and robust cash flow, and an attractive valuation with a low P/E and high dividend yield. However, the score is significantly weighed down by weak technicals, with the stock in a clear downtrend and showing bearish momentum. The recent compression in gross margins is a key risk to monitor.
HC Surgical Specialists Ltd (1B1) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 47.55M
- Dividend Yield
- 6.71%
- Average Volume (3M)
- 17.47K
- Price to Earnings (P/E)
- 7.3
- Beta (1Y)
- 0.28
- Revenue Growth
- 1.42%
- EPS Growth
- -17.12%
- Country
- Singapore
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
HC Surgical Specialists Ltd Business Overview & Revenue Model
Company Description
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and co...
HC Surgical Specialists Ltd Financial Statement Overview
Summary
Overall financial health is strong, driven by a robust balance sheet (Score: 90) with minimal debt and high equity, and excellent cash flow generation (Score: 85) with a 40% operating cash flow margin. The income statement (Score: 70) shows solid profitability but is tempered by a sharp decline in gross margin, which requires monitoring.
Income Statement
70PositiveBalance Sheet
90Very PositiveCash Flow
85Very Positive| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.22M | 19.38M | 19.11M | 18.81M | 19.08M | 19.31M |
| Gross Profit | 8.70M | 6.29M | 16.11M | 15.96M | 16.45M | 16.67M |
| EBITDA | 7.14M | 6.59M | 10.88M | 7.01M | 5.96M | 9.59M |
| Net Income | 8.73M | 6.98M | 8.44M | 3.85M | 2.92M | 6.38M |
Balance Sheet | ||||||
| Total Assets | 28.93M | 32.56M | 27.27M | 27.84M | 31.26M | 30.96M |
| Cash, Cash Equivalents and Short-Term Investments | 6.96M | 8.08M | 5.73M | 8.06M | 10.26M | 6.93M |
| Total Debt | 2.40M | 2.69M | 2.78M | 4.34M | 5.50M | 6.25M |
| Total Liabilities | 6.14M | 11.98M | 6.52M | 13.37M | 19.18M | 19.74M |
| Stockholders Equity | 23.11M | 20.91M | 20.95M | 14.69M | 12.10M | 11.00M |
Cash Flow | ||||||
| Free Cash Flow | 6.85M | 7.71M | 6.75M | 6.23M | 6.51M | 6.83M |
| Operating Cash Flow | 7.33M | 7.80M | 7.23M | 6.30M | 7.22M | 7.05M |
| Investing Cash Flow | 1.53M | 158.00K | -444.00K | 2.84M | -1.72M | -1.99M |
| Financing Cash Flow | -9.11M | -5.28M | -9.05M | -7.97M | -6.24M | -9.12M |
HC Surgical Specialists Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:1B1, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.35, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 30.87 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:1B1.
HC Surgical Specialists Ltd Peers Comparison
Overall Rating
SG:OTX74Outperform
SG:1B173Outperform
SG:8K757Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SGD 29.60M | 8.72 | 19.60% | 7.64% | -3.11% | -21.50% | |
| 73Outperform | SGD 47.68M | 7.33 | 29.03% | 6.71% | 1.42% | -17.12% | |
| 57Neutral | SGD 44.29M | 20.88 | 1.27% | ― | 4.69% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:1B1 | HC Surgical Specialists Ltd | 0.31 | -0.01 | -3.13% | |
| SG:1J5 | Hyphens Pharma International Ltd. | 0.35 | 0.03 | 9.37% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.09 | -0.03 | -22.31% | |
| SG:8K7 | UG Healthcare Corp. Ltd. | 0.07 | -0.03 | -27.55% | |
| SG:MIJ | Alliance Healthcare Group Ltd. | 0.18 | 0.06 | 55.17% | |
| SG:OTX | Medinex Ltd. | 0.22 | -0.00 | -1.35% |
HC Surgical Specialists Ltd Corporate Events
HC Surgical Specialists expands orthopaedic network with new Gleneagles Hospital centre
HC Surgical Specialists’ associated company Total Orthopaedics Pte. Ltd. has secured a medical licence for its new orthopaedic centre, Total Orthopaedic Care & Surgery (GEH), at Gleneagles Hospital, marking the group’s first orthopaedic clinic within...
HC Surgical Specialists Secures Unanimous Shareholder Backing at 2026 AGM
HC Surgical Specialists held its annual general meeting in Singapore on 29 September 2026, where shareholders reviewed the FY2026 audited financial statements and received updates on business performance, including non-operating income, dividend yiel...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026
